AbbVie's 'drip-feed' of patents shields top cancer drug from competition, group says

Many of the patent applications for the blood cancer medicine Imbruvica were filed after the drug's initial approval in 2013, part of a strategy by its developer AbbVie to extend by years the market exclusivity for what's become one of its top-selling medicines.